Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name (Ascending) Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
50419-0050-30 50419-0050 Sargramostim Leukine Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor March 5, 1991 Sept. 21, 2012 No Longer Used
54868-3188-00 54868-3188 Sargramostim Leukine Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Dec. 1, 1996 June 30, 2012 No Longer Used
58468-0181-01 58468-0181 Sargramostim Leukine Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor March 15, 2010 Dec. 31, 2013 No Longer Used
58468-0181-02 58468-0181 Sargramostim Leukine Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor March 15, 2010 Dec. 31, 2013 No Longer Used
58468-0180-01 58468-0180 Sargramostim Leukine Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Aug. 5, 2013 June 30, 2016 No Longer Used
58468-0180-02 58468-0180 Sargramostim Leukine Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor March 15, 2010 June 30, 2016 No Longer Used
00024-5843-01 00024-5843 Sargramostim Leukine 250.0 ug/mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous Nov. 5, 2013 Dec. 30, 2021 No Longer Used
00024-5843-05 00024-5843 Sargramostim Leukine 250.0 ug/mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous May 1, 1991 Dec. 30, 2021 No Longer Used
00024-5844-01 00024-5844 Sargramostim Leukine 500.0 ug/mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous Dec. 1, 1996 Dec. 30, 2021 No Longer Used
00024-5844-05 00024-5844 Sargramostim Leukine 500.0 ug/mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous, Subcutaneous Dec. 1, 1996 Dec. 30, 2021 No Longer Used
72237-0101-01 72237-0101 Selinexor XPOVIO 20.0 mg/1 Chemotherapy Enzyme Inhibitor XPO1 Oral July 10, 2019 In Use
72237-0101-02 72237-0101 Selinexor XPOVIO 20.0 mg/1 Chemotherapy Enzyme Inhibitor XPO1 Oral July 10, 2019 In Use
72237-0101-03 72237-0101 Selinexor XPOVIO 20.0 mg/1 Chemotherapy Enzyme Inhibitor XPO1 Oral June 22, 2020 In Use
72237-0101-04 72237-0101 Selinexor XPOVIO 20.0 mg/1 Chemotherapy Enzyme Inhibitor XPO1 Oral July 10, 2019 In Use
72237-0101-05 72237-0101 Selinexor XPOVIO 20.0 mg/1 Chemotherapy Enzyme Inhibitor XPO1 Oral July 10, 2019 In Use
72237-0101-06 72237-0101 Selinexor XPOVIO 20.0 mg/1 Chemotherapy Enzyme Inhibitor XPO1 Oral June 22, 2020 In Use
72237-0101-07 72237-0101 Selinexor XPOVIO 20.0 mg/1 Chemotherapy Enzyme Inhibitor XPO1 Oral June 22, 2020 In Use
00002-2980-26 00002-2980 Selpercatinib RETEVMO 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral May 8, 2020 In Use
00002-2980-60 00002-2980 Selpercatinib RETEVMO 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral May 8, 2020 In Use
00002-3977-60 00002-3977 Selpercatinib RETEVMO 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral May 8, 2020 In Use
00002-5340-60 00002-5340 Selpercatinib RETEVMO 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, RET Oral April 10, 2024 In Use
00002-5562-60 00002-5562 Selpercatinib RETEVMO 160.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, RET Oral April 10, 2024 In Use
00002-6082-60 00002-6082 Selpercatinib RETEVMO 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, RET Oral April 10, 2024 In Use
00002-6120-60 00002-6120 Selpercatinib RETEVMO 120.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, RET Oral April 10, 2024 In Use
57894-0421-01 57894-0421 Siltuximab Sylvant 400.0 mg/1 Immunotherapy Monoclonal Antibody Interleukin-6 Antagonists Intravenous April 1, 2014 Jan. 31, 2021 No Longer Used

Found 10,000 results in 12 milliseconds — Export these results